Core Insights - Abbott reported revenue of 10.64billionforthequarterendedSeptember2024,reflectingayear−over−yearincreaseof4.91.21, up from 1.14inthesamequarterlastyear[1]−TherevenueexceededtheZacksConsensusEstimateof10.56 billion by 0.71%, while the EPS also surpassed the consensus estimate of 1.20by0.83950 million, exceeding the average estimate of 918.13million,withayear−over−yearincreaseof10.51.12 billion, below the average estimate of 1.26billion,representingayear−over−yeardeclineof81.38 billion, slightly below the average estimate of 1.39billion,withayear−over−yeardecreaseof3.91.03 billion, surpassing the average estimate of 919.77million,reflectingayear−over−yearincreaseof1.92.41 billion, exceeding the average estimate of 2.31billion,withayear−over−yeardeclineof1.51.73 billion, slightly above the average estimate of 1.72billion,withayear−over−yearincreaseof17.22.07 billion, below the average estimate of 2.17billion,representingayear−over−yeardeclineof0.3597 million, slightly above the average estimate of 595.52million,withayear−over−yearincreaseof64.75 billion, exceeding the average estimate of 4.70billion,withayear−over−yearincreaseof11.7236 million, below the average estimate of 242.90million,withayear−over−yearincreaseof41.41 billion, matching the average estimate, with a year-over-year increase of 2.8% [2] - Medical Devices - Vascular: Net sales of 699million,slightlyabovetheaverageestimateof695.35 million, with a year-over-year increase of 4% [2] Stock Performance - Abbott's shares have returned -1.8% over the past month, while the Zacks S&P 500 composite has increased by 3.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]